Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds

Core Insights - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is recognized as a leading gene therapy stock favored by hedge funds [1] - The FDA approved Dupixent® (dupilumab) for treating allergic fungal rhinosinusitis (AFRS) in patients aged 6 years and older [1][2] - The approval of Dupixent expands Regeneron's indications in sino-nasal diseases, now including AFRS alongside chronic rhinosinusitis with nasal polyps [2] - Dupixent is the first treatment specifically approved for AFRS, providing potential relief for patients suffering from debilitating symptoms [3] - Regeneron also announced the FDA's acceptance for Priority Review of the Biologics License Application for garetosmab, targeting fibrodysplasia ossificans progressiva, with a decision expected by August 2026 [4] - Garetosmab is a monoclonal antibody that inhibits Activin A, a protein linked to the development of heterotopic ossification lesions in affected individuals [4] - Regeneron develops therapies for various diseases, including cancer, eye disorders, and allergic conditions [5]